CD274 and neoplasm: The tumor proportion score (TPS) of PD-L1 evaluated using the anti-PD-L1 antibody 22C3 stratified progression-free survival (PFS) and objective response rate (ORR) in patients with NSCLC treated with pembrolizumab [2].